文献速递结核与非结核分枝杆菌

全反式维甲酸辅助治疗通过免疫调节提高小鼠抗结核抗生素疗效

Adjunct Therapy With All-trans-Retinoic Acid Improves Therapeutic Efficacy Through Immunomodulation While Treating Tuberculosis With Antibiotics in Mice.
PubMed 文献 · J Infect Dis · 2024-01-01

研究在小鼠结核模型中发现,全反式维甲酸(ATRA)联合异烟肼可改善结核分枝杆菌清除,其机制涉及促进巨噬细胞溶酶体和线粒体活性、上调脂质代谢基因,并激活MEK/ERK及p38 MAPK通路,诱导Th1和Th17应答。作者认为ATRA具有辅助治疗价值,值得进一步人体试验。

要点

  • ATRA联合异烟肼改善小鼠结核分枝杆菌清除。
  • ATRA增强巨噬细胞溶酶体、线粒体活性及炎症介质产生。
  • ATRA激活MEK/ERK和p38 MAPK通路并诱导Th1、Th17应答。

核心结论

  • ATRA通过调节MEK/ERK和p38 MAPK通路提供有益的辅助治疗价值,值得进一步人体试验。

研究设计与样本

  • 小鼠结核感染模型研究,评估ATRA联合异烟肼治疗的效果及免疫调节机制。

主要发现

  • ATRA联合异烟肼改善小鼠结核分枝杆菌清除。
  • ATRA促进巨噬细胞溶酶体和线粒体活性及多种炎症介质产生。
  • ATRA上调巨噬细胞脂质代谢通路基因表达。
  • 体外实验中ATRA激活巨噬细胞MEK/ERK通路,小鼠体内激活MEK/ERK和p38 MAPK通路。
  • ATRA诱导结核分枝杆菌感染小鼠肺和脾中Th1和Th17应答。

临床怎么用

  • 原文未据此给出临床推荐。

局限性

  • 原文结论指出ATRA值得进一步人体试验,提示当前证据仅限于小鼠研究。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Tuberculosis is the second leading infectious killer after coronavirus disease 2019 (COVID-19). Standard antitubercular drugs exhibit various limitations like toxicity, long treatment regimens, and lack of effect against dormant and drug-resistant organisms. Here, we report that all-trans-retinoic acid (ATRA) improves Mycobacterium tuberculosis clearance in mice during treatment with the antitubercular drug isoniazid. Interestingly, ATRA promoted activities of lysosomes and mitochondria, and production of various inflammatory mediators in macrophages. Furthermore, ATRA upregulated the expression of genes of lipid metabolism pathways in macrophages. We demonstrated that ATRA activated the MEK/ERK pathway in macrophages in vitro and MEK/ERK and p38 MAPK pathways in mice. Finally, ATRA induced both Th1 and Th17 responses in lungs and spleens of M. tuberculosis-infected mice. Together, these data indicate that ATRA provides beneficial adjunct therapeutic value by modulating MEK/ERK and p38 MAPK pathways and thus warrants further testing for human use.

来源:J Infect Dis,查看原文。版权归原作者所有。

引用

  1. Singh B, Pahuja I, Yadav P, et al. Adjunct Therapy With All-trans-Retinoic Acid Improves Therapeutic Efficacy Through Immunomodulation While Treating Tuberculosis With Antibiotics in Mice. J Infect Dis. 2024. PMID: 37863472. doi:10.1093/infdis/jiad460

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。